Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 14/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3908785 | 1.00 | OPRM1 (0.45) | OPRM1CCR5FAAHTRPV1 | |
| SCHEMBL3900977 | 1.00 | OPRM1 (0.45) | OPRM1CCR5FAAHTRPV1 | |
| SCHEMBL3908788 | 1.00 | OPRM1 (0.45) | OPRM1CCR5FAAHTRPV1 | |
| SCHEMBL3897943 | 1.00 | OPRM1 (0.45) | OPRM1CCR5FAAHTRPV1 | |
| SCHEMBL3900984 | 0.99 | OPRM1 (0.46) | OPRM1CCR5FAAHTRPV1 | |
| SCHEMBL3903710 | 0.88 | TYMP (0.39) | OPRM1 | |
| SCHEMBL28009777 | 0.88 | DHODH (0.35) | OPRM1 | |
| SCHEMBL28009779 | 0.88 | DHODH (0.35) | OPRM1 | |
| SCHEMBL10048656 | 0.82 | DHODH (0.38) | OPRM1 | |
| SCHEMBL10048510 | 0.82 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622598-B2 | Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622598-B2 | Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622598-B2 | Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-11-24 | — | — | US | disclosed |
| EP-1681280-B1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ARIGEN PHARMACEUTICALS INC (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ARIGEN, INC. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ARIGEN, INC. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ARIGEN, INC. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1681280-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | aRigen, Inc. (JP) | 2006-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | TYR, H1-3, H1-0 | OPRM1 2281/4885CCR5 827/4885FAAH 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.